Characteristics of multiple sclerosis at onset and delay of diagnosis and treatment in Spain (the Novo Study).
Multiple sclerosis (MS) is a disease supposedly of autoimmune origin, with reactivity directed against myelin antigens. From the neuropathological point of view, MS produces inflammation, demyelination and axonal and neuronal degeneration. Inflammatory phenomena are predominant in the initial phase of the disease, followed later by neurodegenerative processes. Over the last decade, early treatment, during the most inflammatory phase of the disease, has been considered the best strategy to treat MS. Accordingly, we decided to determine the periods of delay between the first symptoms and the time to the first medical visit, the time to referral to a specialised MS unit, the delay in undertaking clinical and paraclinical tests, the diagnostic criteria used and the overall delay in diagnosis and treatment. The median time from onset of first symptoms to the first visit to a physician was 19.2 months, which represented the greatest delay. The median time between this initial medical consultation and the confirmation of the diagnosis by a specialised MS unit was 5.7 months, and the overall time from symptom onset to diagnosis was 24.9 months (2.08 years). The median time between onset of the first symptoms and the decision to give the first treatment was 2 years. The most important delay was that from symptom onset to the first medical visit, with the other delays being less. Thus, it is during this initial period that greater effort is required in order to reduce the time to diagnosis, by increasing awareness of the problem of MS among the general population and primary care physicians.
Fernández
O
O
Hospital Regional Universitario Carlos Haya, Málaga, Spain. oscar.fernandez.sspa@juntadeandalucia.es
Fernández
V
V
Arbizu
T
T
Izquierdo
G
G
Bosca
I
I
Arroyo
R
R
García Merino
J A
JA
de Ramón
E
E
D000293:Adolescent; D000328:Adult; D017668:Age of Onset; D000554:Ambulatory Care Facilities / Q000639:trends; D002648:Child; D003955:Diagnostic Tests, Routine / Q000639:trends; D042241:Early Diagnosis; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy*; D010342:Patient Acceptance of Health Care; D011785:Quality Assurance, Health Care / Q000379:methods*; D011787:Quality of Health Care / Q000706:statistics & numerical data / Q000639:trends*; D013030:Spain / Q000453:epidemiology; D013997:Time Factors; D055815:Young Adult
Curr Opin Neurol. 2000 Jun;13(3):255-61
10871248
Lancet. 2009 Oct 31;374(9700):1503-11
19815268
Arch Immunol Ther Exp (Warsz). 2000;48(5):347-51
11140461
Lancet. 2008 Oct 25;372(9648):1502-17
18970977
Mult Scler. 2009 Oct;15(10):1175-82
19737851
Arch Neurol. 2006 Dec;63(12):1686-91
17172607
Neurology. 2000 Feb 22;54(4):807-12
10690967
Ann Neurol. 2000 Jun;47(6):707-17
10852536
Nervenarzt. 2006 Dec;77(12):1506-18
17136556
Eur J Neurol. 2007 Aug;14(8):885-9
17662009
Neurology. 2008 Jan 29;70(5):332-3
18227414
Clin Ther. 2009 Jun;31(6):1142-57
19695384
J Neurol. 2008 Jul;255(7):1023-31
18535872
Brain. 2006 Mar;129(Pt 3):606-16
16415308
J Neurol. 2009 Jul;256(7):1061-6
19252775
Ann Neurol. 1983 Mar;13(3):227-31
6847134
J Eval Clin Pract. 2008 Jun;14(3):460-4
18373567
Ther Clin Risk Manag. 2008 Jun;4(3):627-30
18827858
J Neurosci Nurs. 2008 Jun;40(3):150-7
18578273
Neurologist. 2002 Jul;8(4):227-36
12803682
Clin Neurol Neurosurg. 2008 Mar;110(3):233-8
18093725
Lancet Neurol. 2005 May;4(5):281-8
15847841
Arch Neurol. 2009 Jul;66(7):841-6
19597085
Neurology. 2008 Dec 9;71(24 Suppl 3):S3-7
19064872
Ann Neurol. 2005 Dec;58(6):840-6
16283615
Lancet. 2004 Oct 23-29;364(9444):1489-96
15500893
N Engl J Med. 1998 Jan 29;338(5):278-85
9445407
N Engl J Med. 2008 Oct 23;359(17):1786-801
18946064
Can J Neurol Sci. 2004 May;31(2):157-68
15198439
N Engl J Med. 2002 Jan 17;346(3):158-64
11796849
Lancet Neurol. 2008 Feb;7(2):173-83
18207115
Int MS J. 2007 Mar;14(1):5-10
17509246
Electroencephalogr Clin Neurophysiol Suppl. 1999;49:13-8
10533079
Neurology. 2007 Feb 13;68(7):496-500
17296915
Neurology. 1983 Nov;33(11):1444-52
6685237
Mult Scler. 2002 Feb;8(1):19-23
11936483
Ann Neurol. 2001 Jul;50(1):121-7
11456302
J Immunol. 2005 Aug 1;175(3):1974-82
16034142
Neurology. 2009 Mar 3;72(9):800-5
19073949
Arch Neurol. 2007 Feb;64(2):190-4
17296834
Annu Rev Neurosci. 2008;31:247-69
18558855
Neurol Clin. 2005 Feb;23(1):17-38, v
15661086
Lancet. 2007 Aug 4;370(9585):389-97
17679016
J Neurol. 2008 Apr;255(4):480-7
18004635
Curr Top Microbiol Immunol. 2008;318:19-43
18219813
Curr Neurol Neurosci Rep. 2008 Jan;8(1):1-4
18367032
Neurology. 2005 Oct 11;65(7):1066-70
16217060
BMC Neurol. 2009 May 20;9:19
19457248
Lancet Neurol. 2008 Sep;7(9):852-8
18703007
J Neuroimmunol. 2006 Nov;180(1-2):17-28
16945427
J Neuroimmunol. 2009 Jul 25;212(1-2):121-4
19457560
Brain. 2003 Apr;126(Pt 4):770-82
12615637
N Engl J Med. 2000 Sep 28;343(13):898-904
11006365
Neurol Clin. 1995 Feb;13(1):119-46
7739500
J Neurol Neurosurg Psychiatry. 2006 Sep;77(9):1030-5
16735397
Trends Mol Med. 2001 Mar;7(3):115-21
11286782